Thyroid cancer is the most frequent endocrine malignancy with the majority of cases derived from thyroid follicular cells and caused by sporadic mutations. However, when at least two or more first degree relatives present thyroid cancer, it is classified as familial non-medullary thyroid cancer (FNMTC) that may comprise 3–9% of all thyroid cancer. In this context, 5% of FNMTC are related to hereditary syndromes such as Cowden and Werner Syndromes, displaying specific genetic predisposition factors. On the other hand, the other 95% of cases are classified as non-syndromic FNMTC. Over the last 20 years, several candidate genes emerged in different studies of families worldwide. Nevertheless, the identification of a prevalent polymorphism or germinative mutation has not progressed in FNMTC. In this work, an overview of genetic alteration related to syndromic and non-syndromic FNMTC is presented.
20 February 2022 in Journal of the Endocrine Society
The presence of a bidirectional risk for metachronous carcinomas among women with thyroid and breast cancer is well established. However, the underlying risk factors remain poorly understood. Two sisters developed papillary thyroid cancer (PTC) at age 32 and 34 years, followed by ductal carcinoma of the breast at 44 and 42 years. The 2 children of the younger sister developed ataxia-telangiectasia; the son also developed lymphoblastic lymphoma and his sister died secondary to acute lymphoblastic leukemia (ALL). They were found to be compound heterozygous for ataxia telangiectasia mutated (ATM) gene mutations (c.3848T>C, p.L1283P; and c.802C>T, p.Q268X). Exome sequencing of the 2 sisters (mother and aunt of the children with ataxia-telangiectasia) led to the detection of the pathogenic monoallelic ATM mutation in both of them (c.3848T>C; minor allele frequency [MAF] < 0.01) but detected no other variants known to confer a risk for PTC or breast cancer. The findings suggest that monoallelic ATM mutations, presumably in conjunction with additional genetic and/or nongenetic factors, can confer a risk for developing PTC and breast cancer.
Objective: Familial non-medullary thyroid cancer (FNMTC) is defined as non-medullary thyroid cancer occurring in two or more first-degree relatives, without features of known hereditary syndromes. Although familial predisposition is well established, its clinical behavior remains debated. This study aimed at characterizing familial cases compared to sporadic non-medullary thyroid cancer (SNMTC). Subjects and methods: FNMTC and SNMTC patients were recruited from the Endocrine Division (SEMPR) of the Federal University of Paraná, Brazil, and private endocrine clinics in Curitiba, Paraná, Brazil [...] ABSTRACT Objective: Familial non-medullary thyroid cancer (FNMTC) is defined as non-medullary thyroid cancer occurring in two or more first-degree relatives, without features of known hereditary syndromes. Although familial predisposition is well established, its clinical behavior remains debated. This study aimed at characterizing familial cases compared to sporadic non-medullary thyroid cancer (SNMTC). Subjects and methods: FNMTC and SNMTC patients were recruited from the Endocrine Division (SEMPR) of the Federal University of Paraná, Brazil, and private endocrine clinics in Curitiba, Paraná, Brazil
1 January 2026 in Archives of Endocrinology and Metabolism
Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group [...] ABSTRACT Objective: To evaluate and describe the changes in the therapeutic approach to Graves’ disease at a tertiary hospital center over a 20-year period, with an emphasis on the frequency of prescription and the timing of radioactive iodine indication. Subjects and methods: We conducted a retrospective analysis of data from medical records of patients recently diagnosed with Graves’ disease (GD) and followed up at a single institution during two consecutive periods: Group A diagnosed between 2002 and 2010, and Group